BR0108401A - Análogos de nucleosìdeos com base bicìclica modificada por carboxamidina - Google Patents
Análogos de nucleosìdeos com base bicìclica modificada por carboxamidinaInfo
- Publication number
- BR0108401A BR0108401A BR0108401-1A BR0108401A BR0108401A BR 0108401 A BR0108401 A BR 0108401A BR 0108401 A BR0108401 A BR 0108401A BR 0108401 A BR0108401 A BR 0108401A
- Authority
- BR
- Brazil
- Prior art keywords
- carboxamidine
- modified
- bicyclically
- nucleoside analogs
- based nucleoside
- Prior art date
Links
- 239000002777 nucleoside Substances 0.000 title abstract 2
- 150000003833 nucleoside derivatives Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010061217 Infestation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940127073 nucleoside analogue Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18267600P | 2000-02-15 | 2000-02-15 | |
| US09/595,365 US6455508B1 (en) | 2000-02-15 | 2000-10-05 | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
| PCT/US2001/005172 WO2001060381A1 (en) | 2000-02-15 | 2001-02-15 | Nucleoside analogs with carboxamidine-modified bicyclic base |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0108401A true BR0108401A (pt) | 2004-01-06 |
Family
ID=26878297
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0108401-1A BR0108401A (pt) | 2000-02-15 | 2001-02-15 | Análogos de nucleosìdeos com base bicìclica modificada por carboxamidina |
| BR0108402-0A BR0108402A (pt) | 2000-02-15 | 2001-02-15 | Análogos de nucleosìdeo com base monocìclica carboxamidina modificado |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0108402-0A BR0108402A (pt) | 2000-02-15 | 2001-02-15 | Análogos de nucleosìdeo com base monocìclica carboxamidina modificado |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6455508B1 (https=) |
| EP (3) | EP1813278B9 (https=) |
| JP (3) | JP4975930B2 (https=) |
| KR (2) | KR100811927B1 (https=) |
| CN (2) | CN1268335C (https=) |
| AT (1) | ATE377422T1 (https=) |
| AU (2) | AU783142B2 (https=) |
| BR (2) | BR0108401A (https=) |
| CA (2) | CA2395854A1 (https=) |
| CY (1) | CY1107103T1 (https=) |
| CZ (2) | CZ302327B6 (https=) |
| DE (1) | DE60131250T8 (https=) |
| DK (1) | DK1257281T3 (https=) |
| ES (2) | ES2295148T3 (https=) |
| HR (2) | HRP20020583A2 (https=) |
| HU (2) | HU229480B1 (https=) |
| IL (3) | IL150555A0 (https=) |
| MX (2) | MXPA02007932A (https=) |
| NO (2) | NO329927B1 (https=) |
| NZ (2) | NZ521390A (https=) |
| PL (2) | PL365239A1 (https=) |
| PT (1) | PT1257281E (https=) |
| RS (1) | RS20090086A (https=) |
| RU (2) | RU2259831C2 (https=) |
| SI (2) | SI21077A (https=) |
| SK (2) | SK287765B6 (https=) |
| WO (2) | WO2001060379A1 (https=) |
| YU (1) | YU61502A (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6831069B2 (en) * | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| US7638496B2 (en) * | 2000-02-15 | 2009-12-29 | Valeant Pharmaceuticals North America | Nucleoside analogs with carboxamidine modified monocyclic base |
| US7056895B2 (en) * | 2000-02-15 | 2006-06-06 | Valeant Pharmaceuticals International | Tirazole nucleoside analogs and methods for using same |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| KR20080021797A (ko) | 2000-05-26 | 2008-03-07 | 이데닉스(케이만)리미티드 | 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물 |
| WO2002057425A2 (en) | 2001-01-22 | 2002-07-25 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| WO2003037908A1 (en) * | 2001-10-31 | 2003-05-08 | Ribapharm Inc. | Antiviral combination therapy and compositions |
| NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| PL374781A1 (en) | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| HUE033832T2 (en) | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation |
| RU2005121904A (ru) | 2002-12-12 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | Способ получения 2`-разветвленных нуклеозидов |
| RU2005133093A (ru) * | 2003-03-28 | 2006-07-27 | Фармассет, Инк. (Us) | Соединения для лечения флавивирусных инфекций |
| US20040197292A1 (en) * | 2003-04-04 | 2004-10-07 | The Procter & Gamble Company | Personal care composition containing an antidandruff component and a nonionic surfactant |
| US20040202636A1 (en) * | 2003-04-11 | 2004-10-14 | Kaczvinsky Joseph Robert | Personal care composition containing an antidandruff component and a nonionic surfactant |
| US20040197287A1 (en) * | 2003-04-04 | 2004-10-07 | The Procter & Gamble Company | Personal care composition containing an antidandruff component and a nonionic surfactant |
| US6930093B2 (en) * | 2003-07-10 | 2005-08-16 | Valeant Research & Development | Use of ribofuranose derivatives against inflammatory bowel diseases |
| US20050009848A1 (en) * | 2003-07-10 | 2005-01-13 | Icn Pharmaceuticals Switzerland Ltd. | Use of antivirals against inflammatory bowel diseases |
| WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
| US20050095218A1 (en) * | 2003-10-29 | 2005-05-05 | The Procter & Gamble Company | Personal care composition containing a detersive surfactant, an antidandruff component, and ketoamide surfactants |
| US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
| AU2005254057B2 (en) | 2004-06-15 | 2011-02-17 | Isis Pharmaceuticals, Inc. | C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase |
| JP4516863B2 (ja) * | 2005-03-11 | 2010-08-04 | 株式会社ケンウッド | 音声合成装置、音声合成方法及びプログラム |
| CA2606195C (en) | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Hcv ns3 protease inhibitors |
| AR057456A1 (es) | 2005-07-20 | 2007-12-05 | Merck & Co Inc | Inhibidores de la proteasa ns3 del vhc |
| NZ565269A (en) | 2005-08-01 | 2010-03-26 | Merck & Co Inc | Macrocyclic peptides as HCV NS3 protease inhibitors |
| EP1976382B1 (en) | 2005-12-23 | 2013-04-24 | IDENIX Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
| US8497292B2 (en) | 2005-12-28 | 2013-07-30 | Translational Therapeutics, Inc. | Translational dysfunction based therapeutics |
| WO2007123579A2 (en) * | 2005-12-28 | 2007-11-01 | Translational Therapeutics | Translational dysfunction based therapeutics |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| WO2008005542A2 (en) * | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc., | Antiviral phosphinate compounds |
| AU2007309488B2 (en) | 2006-10-24 | 2012-10-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| CA2667146C (en) | 2006-10-24 | 2016-01-19 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| AU2007309546A1 (en) | 2006-10-24 | 2008-05-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HCV NS3 protease inhibitors |
| BRPI0718161A2 (pt) | 2006-10-27 | 2013-11-26 | Merck & Co Inc | Composto, composição farmacêutica, e, uso do composto. |
| US8377874B2 (en) | 2006-10-27 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| CA2672250C (en) | 2006-12-20 | 2013-04-30 | Ian Stansfield | Antiviral indoles |
| GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| JP2010533699A (ja) | 2007-07-17 | 2010-10-28 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | C型肝炎感染症の治療のための大環状インドール誘導体 |
| AU2008277377B2 (en) | 2007-07-19 | 2013-08-01 | Msd Italia S.R.L. | Macrocyclic compounds as antiviral agents |
| WO2009134624A1 (en) | 2008-04-28 | 2009-11-05 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| EA019327B1 (ru) | 2008-07-22 | 2014-02-28 | Мерк Шарп Энд Домэ Корп. | Макроциклическое хиноксалиновое соединение в качестве ингибитора протеазы вгс ns3 |
| WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
| GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
| US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
| EP2780026B1 (en) | 2011-11-15 | 2019-10-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| WO2013106344A1 (en) | 2012-01-12 | 2013-07-18 | Ligand Pharmaceuticals, Inc. | 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5' |
| CN102978264B (zh) * | 2012-11-14 | 2014-12-10 | 广东肇庆星湖生物科技股份有限公司 | 一种他立韦林的制备方法 |
| WO2014121418A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
| WO2014121417A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
| JP2017512183A (ja) | 2014-02-13 | 2017-05-18 | リガンド・ファーマシューティカルズ・インコーポレイテッド | プロドラッグ化合物およびそれらの使用 |
| CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
| EA201890454A1 (ru) * | 2015-08-06 | 2018-07-31 | Чимерикс, Инк. | Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств |
| WO2019060692A1 (en) | 2017-09-21 | 2019-03-28 | Chimerix, Inc. | MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES |
| RU2020126177A (ru) | 2018-01-09 | 2022-02-10 | Лиганд Фармасьютикалз, Инк. | Ацетальные соединения и их терапевтическое применение |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3984396A (en) | 1971-06-01 | 1976-10-05 | Icn Pharmaceuticals, Inc. | 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters |
| US3798209A (en) | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
| US3991078A (en) | 1971-06-01 | 1976-11-09 | Icn Pharmaceuticals, Inc. | N-substituted 1,2,4-triazoles |
| USRE29835E (en) | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
| US3962211A (en) * | 1975-01-13 | 1976-06-08 | The University Of Utah | 7-substituted nucleoside compounds |
| US4093624A (en) | 1977-01-31 | 1978-06-06 | Icn Pharmaceuticals, Inc. | 1,2,4-Thiadiazolidine-3,5-dione |
| SU1124559A1 (ru) * | 1983-06-08 | 1986-07-07 | Институт молекулярной биологии АН СССР | 1-(2-Оксиэтоксиметил)-1,2,4-триазол-5-карбоксамид,обладающий активностью противвируса герпеса |
| JPS6426593A (en) | 1987-07-21 | 1989-01-27 | Asahi Glass Co Ltd | Nucleoside derivative |
| US4892865A (en) * | 1987-12-01 | 1990-01-09 | The Regents Of The University Of Michigan | Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents |
| US5405837A (en) * | 1993-05-18 | 1995-04-11 | Indiana University Foundation | Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin |
| RU2186569C2 (ru) * | 1996-01-23 | 2002-08-10 | Ай-Си-Эн ФАРМАСЬЮТИКАЛЗ | Модуляция экспрессии тн1/тн2 цитокинов рибавирином и аналогами рибавирина в активированных т-лимфоцитах |
| US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
| IL129126A0 (en) * | 1996-10-16 | 2000-02-17 | Icn Pharmaceuticals | Monocyclic l-nucleosides analogs and uses thereof |
| WO2001027114A1 (en) * | 1999-08-27 | 2001-04-19 | Icn Pharmaceuticals, Inc. | PYRROLO[2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS |
-
2000
- 2000-10-05 US US09/595,365 patent/US6455508B1/en not_active Expired - Lifetime
-
2001
- 2001-02-15 JP JP2001559475A patent/JP4975930B2/ja not_active Expired - Fee Related
- 2001-02-15 WO PCT/US2001/040148 patent/WO2001060379A1/en not_active Ceased
- 2001-02-15 IL IL15055501A patent/IL150555A0/xx unknown
- 2001-02-15 JP JP2001559477A patent/JP2004510691A/ja active Pending
- 2001-02-15 NZ NZ521390A patent/NZ521390A/en unknown
- 2001-02-15 YU YU61502A patent/YU61502A/sh unknown
- 2001-02-15 AU AU47988/01A patent/AU783142B2/en not_active Ceased
- 2001-02-15 RS RSP-2009/0086A patent/RS20090086A/sr unknown
- 2001-02-15 HU HU0300027A patent/HU229480B1/hu unknown
- 2001-02-15 IL IL15099001A patent/IL150990A0/xx unknown
- 2001-02-15 BR BR0108401-1A patent/BR0108401A/pt not_active IP Right Cessation
- 2001-02-15 SI SI200120011A patent/SI21077A/sl not_active IP Right Cessation
- 2001-02-15 MX MXPA02007932A patent/MXPA02007932A/es unknown
- 2001-02-15 SK SK1149-2002A patent/SK287765B6/sk not_active IP Right Cessation
- 2001-02-15 AU AU38450/01A patent/AU3845001A/en not_active Abandoned
- 2001-02-15 EP EP07107588.1A patent/EP1813278B9/en not_active Expired - Lifetime
- 2001-02-15 RU RU2002120922/15A patent/RU2259831C2/ru active
- 2001-02-15 PT PT01920996T patent/PT1257281E/pt unknown
- 2001-02-15 HR HR20020583A patent/HRP20020583A2/xx not_active Application Discontinuation
- 2001-02-15 ES ES01920996T patent/ES2295148T3/es not_active Expired - Lifetime
- 2001-02-15 BR BR0108402-0A patent/BR0108402A/pt not_active Application Discontinuation
- 2001-02-15 CZ CZ20022798A patent/CZ302327B6/cs not_active IP Right Cessation
- 2001-02-15 DK DK01920996T patent/DK1257281T3/da active
- 2001-02-15 MX MXPA02007931A patent/MXPA02007931A/es active IP Right Grant
- 2001-02-15 EP EP01920996A patent/EP1257281B8/en not_active Expired - Lifetime
- 2001-02-15 HU HU0300912A patent/HUP0300912A2/hu unknown
- 2001-02-15 CZ CZ20022799A patent/CZ20022799A3/cs unknown
- 2001-02-15 KR KR1020027010417A patent/KR100811927B1/ko not_active Expired - Fee Related
- 2001-02-15 AT AT01920996T patent/ATE377422T1/de active
- 2001-02-15 EP EP01910892A patent/EP1278528A4/en not_active Withdrawn
- 2001-02-15 KR KR1020027010593A patent/KR20030005190A/ko not_active Withdrawn
- 2001-02-15 SI SI200120010A patent/SI21076A/sl not_active IP Right Cessation
- 2001-02-15 HR HR20020657A patent/HRP20020657A2/hr not_active Application Discontinuation
- 2001-02-15 WO PCT/US2001/005172 patent/WO2001060381A1/en not_active Ceased
- 2001-02-15 CA CA002395854A patent/CA2395854A1/en not_active Abandoned
- 2001-02-15 RU RU2002120483/14A patent/RU2002120483A/ru not_active Application Discontinuation
- 2001-02-15 DE DE60131250T patent/DE60131250T8/de active Active
- 2001-02-15 ES ES07107588.1T patent/ES2528429T3/es not_active Expired - Lifetime
- 2001-02-15 SK SK1157-2002A patent/SK11572002A3/sk unknown
- 2001-02-15 CA CA2399208A patent/CA2399208C/en not_active Expired - Fee Related
- 2001-02-15 NZ NZ52087701A patent/NZ520877A/xx not_active IP Right Cessation
- 2001-02-15 CN CNB018077455A patent/CN1268335C/zh not_active Expired - Fee Related
- 2001-02-15 CN CN01805036A patent/CN1420779A/zh active Pending
- 2001-02-15 PL PL01365239A patent/PL365239A1/xx unknown
- 2001-02-15 PL PL357945A patent/PL200140B1/pl unknown
-
2002
- 2002-07-30 IL IL150990A patent/IL150990A/en not_active IP Right Cessation
- 2002-08-14 NO NO20023855A patent/NO329927B1/no not_active IP Right Cessation
- 2002-08-14 NO NO20023852A patent/NO20023852L/no not_active Application Discontinuation
-
2007
- 2007-12-19 CY CY20071101614T patent/CY1107103T1/el unknown
-
2009
- 2009-01-29 JP JP2009018382A patent/JP5253204B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0108401A (pt) | Análogos de nucleosìdeos com base bicìclica modificada por carboxamidina | |
| ATE157257T1 (de) | Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen | |
| WO1997049373A3 (en) | Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin | |
| BR9714349A (pt) | L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos | |
| BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
| BR0010476A (pt) | Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais | |
| BR0108435A (pt) | Formulação e uso de entecavir de baixa dose | |
| PT979244E (pt) | Derivados de ciclosporina, sua preparacao e composicoes farmaceuticas que os contem | |
| BR9814956A (pt) | Inibidores de benzotiazol da tirosina cinase de proteìna | |
| BR9909730A (pt) | Dihidropirimidinas | |
| BR0007435A (pt) | Formulações e métodos para tratamento decondições associadas com mucosa com ummodificador de resposta imunológica | |
| BRPI0518861A2 (pt) | compostos, sais ou hidratos farmaceuticamente aceitos, composição farmacêutica e métodos de modulação de atividades imuno das citocinas e de tratamento da infecção por vìrus da hepatite c em paciente | |
| DE69920757D1 (de) | Immunsuppressive wirkungen von pteridinderivaten | |
| SE8802569L (sv) | Foerbaettringar vid eller avseende somatosstatiner | |
| DE69027031D1 (de) | Nicht glycosierte proteine, analoge des menschlichen interleukin-3 | |
| ATE125706T1 (de) | Diphosphonate enthaltende pharmazeutische zusammensetzungen zur behandlung von arthrosis. | |
| LV10186A (lv) | Cistina atvasinajumu pielietojums arstniecibas lidzeklu ar imunomodulejosu darbibu pagatavosanai farmaceitiskas kompozicijas uz to bazes | |
| BR9912218A (pt) | Compostos obtidos de espécies de sálvia possuindo atividade antivirótica | |
| ES2061727T3 (es) | Sustancias fisiologicamente activas, un procedimiento para su preparacion y composiciones farmaceuticas que las contienen. | |
| ES2182914T3 (es) | Inmunopotenciacion inducida de quitosan. | |
| BR9812553A (pt) | Formulação medicamentosa com liberação de substância ativa controlada | |
| BR0009476A (pt) | Esteróides imunomoduladores, em particular hemidrato de 16 alfa-bromoepiandrosterona | |
| BG97123A (bg) | Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа | |
| MX9301922A (es) | Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv). | |
| BR0007991A (pt) | Uso do composto ácido (e) -7- [ 4- (4-fluorofenil) -6-isopropil-2- [metil (metilsulfonil) amino] pirimidin -5-il] - (3r, 5s) -3,5-diidroxiept-6-enóico, ou de um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de preparação de uma composição farmacêutica, de redução dos nìveis de c-ldl e da razão de lipìdeo de c-ldl/ c-hdl, e, regime dosagem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008. |